Renal protection in diabetes: Is it affected by glucose control or inhibition of the renin-angiotensin pathway?

Clinical Nephrology

Volumn 69, Issue 3, 2008, Pages 169-178

  Mandal, A K ^a,c   Hiebert, L M ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c NONE   (United States)

Author keywords

ACEI; Clearance; Creatinine; Insulin; Proteinuria; Serum

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CAPTOPRIL; CREATININE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; GLIBENCLAMIDE; GLUCOSE; HEPARIN; HYDRALAZINE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; INSULIN; INSULIN GLARGINE; IRBESARTAN; LISINOPRIL; ORAL ANTIDIABETIC AGENT; PLACEBO; QUINAPRIL;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CELL CULTURE; CELL DAMAGE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ENDOTHELIUM CELL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERGLYCEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LONG TERM CARE; MALE; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL;

EID: 40449126741     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP69169     Document Type: Article

References (42)